Testing av Cabozantinib hos pasienter med avanserte nevroendokrine og karsinoide svulster i bukspyttkjertelen
Randomisert, dobbeltblindet fase III-studie av Cabozantinib versus placebo hos pasienter med avanserte nevroendokrine svulster etter progresjon på tidligere terapi (CABINET)
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Studieoversikt
Status
Status
Forhold
Forhold
- Nevroendokrin svulst
- Fungerende pankreatisk nevroendokrin svulst
- Lungenevroendokrin neoplasma av middels grad
- Lokalt avansert pankreatisk nevroendokrin svulst
- Lokalt avansert ikke-opererbart fordøyelsessystem Nevroendokrin neoplasma
- Lavgradig lunge-nevroendokrin neoplasma
- Metastatisk fordøyelsessystem Nevroendokrin neoplasma
- Metastatisk fordøyelsessystem Nevroendokrin svulst G1
- Metastatisk pankreatisk nevroendokrin svulst
- Nevroendokrin neoplasma
- Ikke-fungerende pankreatisk nevroendokrin svulst
- Pankreatisk serotoninproduserende nevroendokrin svulst
- Lokalt avansert lunge-nevroendokrin neoplasma
- Metastatisk lunge-nevroendokrin neoplasma
- Ikke-opererbar lunge-nevroendokrin neoplasma
- Lokalt avansert fordøyelsessystem nevroendokrin neoplasma
- Lokalt avansert fordøyelsessystem nevroendokrin svulst G1
- Metastatisk pankreatisk nevroendokrin neoplasma
- Ikke-opererbart fordøyelsessystem Nevroendokrin neoplasma
- Ikke-opererbart fordøyelsessystem Nevroendokrin svulst G1
- Ikke-opererbar nevroendokrin neoplasma i bukspyttkjertelen
- Lungenevroendokrin svulst G2
- Metastatisk lunge-nevroendokrin svulst
- Lungenevroendokrin svulst
- Nevroendokrin svulst G2
- Metastatisk Thymus Neuroendokrin Neoplasma
- Thymus nevroendokrin svulst
- Ikke-opererbar nevroendokrin thymus-neoplasma
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To determine whether cabozantinib (cabozantinib S-malate) can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic neuroendocrine tumors (NET) whose disease has progressed after prior therapy.
II. To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
SECONDARY OBJECTIVES:
I. To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.
II. To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
III. To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced pancreatic NET using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
IV. To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced carcinoid tumors using CTCAE and PRO-CTCAE.
V. To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.
VI. To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced carcinoid tumors whose disease has progressed after prior therapy.
OTHER OBJECTIVE:
I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
QUALITY OF LIFE SUBSTUDY OBJECTIVE:
I. To compare overall quality of life, disease-related symptoms, and other domains between the two treatment groups (cabozantinib versus [vs.] placebo) within each cohort of patients (pancreatic NET vs. carcinoid tumor). (Quality of Life Substudy Objective - A021602-HO1)
POPULATION PHARMACOKINETICS SUBSTUDY OBJECTIVE:
I. To describe the population pharmacokinetic and exposure-response relationships of cabozantinib in patients with advanced neuroendocrine tumors. (Population Pharmacokinetics Substudy Objective - A021602-PP1)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and computed tomography (CT), magnetic resonance imaging (MRI), and/or x-ray imaging during screening and on study.
ARM II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.
After completion of study treatment, patients are followed up every 12 weeks until disease progression or start of new anticancer therapy, and then every 6 months until 8 years after registration.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
-
Arizona
-
Kingman, Arizona, Forente stater, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Forente stater, 85054
- Mayo Clinic Hospital in Arizona
-
Tucson, Arizona, Forente stater, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Forente stater, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Antioch, California, Forente stater, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande, California, Forente stater, 93420
- PCR Oncology
-
Auburn, California, Forente stater, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burlingame, California, Forente stater, 94010
- Mills-Peninsula Medical Center
-
Duarte, California, Forente stater, 91010
- City of Hope Comprehensive Cancer Center
-
Dublin, California, Forente stater, 94568
- Epic Care-Dublin
-
Emeryville, California, Forente stater, 94608
- Epic Care Partners in Cancer Care
-
Fremont, California, Forente stater, 94538
- Kaiser Permanente-Fremont
-
Fremont, California, Forente stater, 94538
- Palo Alto Medical Foundation-Fremont
-
Fresno, California, Forente stater, 93720
- Kaiser Permanente-Fresno
-
Martinez, California, Forente stater, 94553-3156
- Contra Costa Regional Medical Center
-
Marysville, California, Forente stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forente stater, 95355
- Memorial Medical Center
-
Modesto, California, Forente stater, 95356
- Kaiser Permanente-Modesto
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Camino Division
-
Oakland, California, Forente stater, 94611
- Kaiser Permanente-Oakland
-
Oakland, California, Forente stater, 94609
- Alta Bates Summit Medical Center - Summit Campus
-
Palo Alto, California, Forente stater, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Forente stater, 94301
- Palo Alto Medical Foundation Health Care
-
Redwood City, California, Forente stater, 94063
- Kaiser Permanente-Redwood City
-
Richmond, California, Forente stater, 94801
- Kaiser Permanente-Richmond
-
Roseville, California, Forente stater, 95661
- Kaiser Permanente-Roseville
-
Roseville, California, Forente stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forente stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forente stater, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Forente stater, 95823
- Kaiser Permanente-South Sacramento
-
Salinas, California, Forente stater, 93901
- Salinas Valley Memorial
-
San Francisco, California, Forente stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forente stater, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Forente stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Jose, California, Forente stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Forente stater, 94577
- Kaiser Permanente San Leandro
-
San Mateo, California, Forente stater, 94401
- Mills Health Center
-
San Rafael, California, Forente stater, 94903
- Kaiser San Rafael-Gallinas
-
San Rafael, California, Forente stater, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Forente stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Cruz, California, Forente stater, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Forente stater, 95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco, California, Forente stater, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Forente stater, 95210
- Kaiser Permanente-Stockton
-
Sunnyvale, California, Forente stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vacaville, California, Forente stater, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Forente stater, 94589
- Kaiser Permanente-Vallejo
-
Vallejo, California, Forente stater, 94589
- Sutter Solano Medical Center/Cancer Center
-
Walnut Creek, California, Forente stater, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Boulder, Colorado, Forente stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Forente stater, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Forente stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Forente stater, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Forente stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood, Colorado, Forente stater, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Forente stater, 80113
- Swedish Medical Center
-
Golden, Colorado, Forente stater, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Forente stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Forente stater, 80631
- Banner North Colorado Medical Center
-
Lafayette, Colorado, Forente stater, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Littleton, Colorado, Forente stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Forente stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Forente stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Forente stater, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Forente stater, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Danbury Hospital
-
Norwalk, Connecticut, Forente stater, 06856
- Norwalk Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- GenesisCare USA - Aventura FP
-
Aventura, Florida, Forente stater, 33180
- GenesisCare USA - Aventura
-
Boca Raton, Florida, Forente stater, 33431
- GenesisCare USA - Boca Ration FP06
-
Fort Myers, Florida, Forente stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Hollywood, Florida, Forente stater, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Forente stater, 32224-9980
- Mayo Clinic in Florida
-
Tampa, Florida, Forente stater, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forente stater, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forente stater, 30342
- Emory Saint Joseph's Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forente stater, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Forente stater, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Forente stater, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Forente stater, 96819
- Kaiser Permanente Moanalua Medical Center
-
‘Aiea, Hawaii, Forente stater, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Forente stater, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Forente stater, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forente stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forente stater, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Forente stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Forente stater, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Washington, Illinois, Forente stater, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
South Bend, Indiana, Forente stater, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Bettendorf, Iowa, Forente stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Forente stater, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Forente stater, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forente stater, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Forente stater, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forente stater, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forente stater, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Forente stater, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Forente stater, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Forente stater, 70360
- Oncology Center of The South Incorporated
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Forente stater, 02118
- Boston Medical Center
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Clinic
-
-
Michigan
-
Adrian, Michigan, Forente stater, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Forente stater, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Forente stater, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Forente stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forente stater, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Forente stater, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Forente stater, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forente stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Forente stater, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Forente stater, 48054
- Henry Ford River District Hospital
-
Farmington Hills, Michigan, Forente stater, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Forente stater, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Forente stater, 48532
- Singh and Arora Hematology Oncology PC
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Forente stater, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Forente stater, 49009
- Beacon Kalamazoo Cancer Center
-
Lansing, Michigan, Forente stater, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Forente stater, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Forente stater, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Forente stater, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Forente stater, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Monroe, Michigan, Forente stater, 48162
- Toledo Clinic Cancer Centers-Monroe
-
Mount Clemens, Michigan, Forente stater, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Forente stater, 48858
- McLaren Cancer Institute-Central Michigan
-
Petoskey, Michigan, Forente stater, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Forente stater, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Forente stater, 48060
- McLaren-Port Huron
-
Port Huron, Michigan, Forente stater, 48060
- Lake Huron Medical Center
-
Port Huron, Michigan, Forente stater, 48060
- Huron Medical Center PC
-
Rochester Hills, Michigan, Forente stater, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Forente stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forente stater, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, Forente stater, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Forente stater, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, Forente stater, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Forente stater, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Forente stater, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Forente stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forente stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Forente stater, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Bemidji, Minnesota, Forente stater, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Forente stater, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Deer River, Minnesota, Forente stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Hibbing, Minnesota, Forente stater, 55746
- Essentia Health Hibbing Clinic
-
Maple Grove, Minnesota, Forente stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55454
- Health Partners Inc
-
New Ulm, Minnesota, Forente stater, 56073
- New Ulm Medical Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Sandstone, Minnesota, Forente stater, 55072
- Essentia Health Sandstone
-
Shakopee, Minnesota, Forente stater, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Forente stater, 55792
- Essentia Health Virginia Clinic
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Forente stater, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Bonne Terre, Missouri, Forente stater, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Forente stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forente stater, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Forente stater, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forente stater, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Forente stater, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Forente stater, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Forente stater, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forente stater, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
Nevada
-
Carson City, Nevada, Forente stater, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Forente stater, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Forente stater, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Forente stater, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Forente stater, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Forente stater, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Forente stater, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Forente stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forente stater, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Forente stater, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Forente stater, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Forente stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forente stater, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Forente stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forente stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forente stater, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Forente stater, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Forente stater, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Forente stater, 89121
- Cancer Therapy and Integrative Medicine
-
Las Vegas, Nevada, Forente stater, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Forente stater, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Forente stater, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Forente stater, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Forente stater, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Forente stater, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Forente stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forente stater, 89169
- University Cancer Center
-
Las Vegas, Nevada, Forente stater, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Forente stater, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Forente stater, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Forente stater, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Forente stater, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Nashua, New Hampshire, Forente stater, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- Memorial Sloan Kettering Basking Ridge
-
Englewood, New Jersey, Forente stater, 07631
- Englewood Hospital and Medical Center
-
Middletown, New Jersey, Forente stater, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Forente stater, 07645
- Memorial Sloan Kettering Bergen
-
Paramus, New Jersey, Forente stater, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Forente stater, 07450
- Valley Health System Ridgewood Campus
-
Wayne, New Jersey, Forente stater, 07470
- Valley Medical Group - Wayne Multispecialty Practice
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Forente stater, 87110
- Presbyterian Kaseman Hospital
-
Rio Rancho, New Mexico, Forente stater, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Auburn, New York, Forente stater, 13021
- Hematology Oncology Associates of Central New York-Auburn
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Camillus, New York, Forente stater, 13031
- Hematology Oncology Associates of CNY at Camillus
-
Commack, New York, Forente stater, 11725
- Memorial Sloan Kettering Commack
-
East Syracuse, New York, Forente stater, 13057
- Hematology Oncology Associates of Central New York-East Syracuse
-
Harrison, New York, Forente stater, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forente stater, 10029
- Mount Sinai Hospital
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
Uniondale, New York, Forente stater, 11553
- Memorial Sloan Kettering Nassau
-
Webster, New York, Forente stater, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Forente stater, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kinston, North Carolina, Forente stater, 28501
- ECU Health Oncology Kinston
-
Washington, North Carolina, Forente stater, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Beachwood, Ohio, Forente stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Forente stater, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Chillicothe, Ohio, Forente stater, 45601
- Adena Regional Medical Center
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forente stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forente stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forente stater, 43215
- Grant Medical Center
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Forente stater, 45409
- Premier Blood and Cancer Center
-
Delaware, Ohio, Forente stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Mansfield, Ohio, Forente stater, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Forente stater, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Forente stater, 43302
- OhioHealth Marion General Hospital
-
Maumee, Ohio, Forente stater, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Maumee, Ohio, Forente stater, 43537
- Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
-
Mentor, Ohio, Forente stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, Forente stater, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Newark, Ohio, Forente stater, 43055
- Licking Memorial Hospital
-
Parma, Ohio, Forente stater, 44129
- University Hospitals Parma Medical Center
-
Perrysburg, Ohio, Forente stater, 43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth, Ohio, Forente stater, 45662
- Southern Ohio Medical Center
-
Toledo, Ohio, Forente stater, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Forente stater, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Wadsworth, Ohio, Forente stater, 44281
- University Hospitals Sharon Health Center
-
Westlake, Ohio, Forente stater, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville, Ohio, Forente stater, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City, Oregon, Forente stater, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forente stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Forente stater, 18301
- Pocono Medical Center
-
Erie, Pennsylvania, Forente stater, 16544
- Saint Vincent Hospital
-
Hazleton, Pennsylvania, Forente stater, 18201
- Lehigh Valley Hospital-Hazleton
-
Jefferson Hills, Pennsylvania, Forente stater, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Forente stater, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- West Penn Hospital
-
Wexford, Pennsylvania, Forente stater, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Forente stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Forente stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Forente stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forente stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Utah
-
Farmington, Utah, Forente stater, 84025
- Farmington Health Center
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forente stater, 84106
- University of Utah Sugarhouse Health Center
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Virginia Mason Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Forente stater, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton, Wisconsin, Forente stater, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Forente stater, 54806
- Duluth Clinic Ashland
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forente stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forente stater, 53188
- ProHealth Waukesha Memorial Hospital
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
-
Wyoming
-
Cody, Wyoming, Forente stater, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Documentation of Disease:
-
Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology
- The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed
- Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma without specification of differentiation status, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible. Patients with well-differentiated grade 3 neuroendocrine tumor are eligible
-
Stage: Locally advanced/unresectable or metastatic disease
-
Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, thymus, other, or unknown primary site; GI, lung, thymus, other, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study
- Functional (i.e., associated with symptoms or clinical syndrome related to hormone secretion by tumor) or nonfunctional tumors are allowed
-
Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submitted
-
-
Measurable Disease
- Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
-
Prior Treatment
- Patient must have experienced disease progression after receiving or intolerance leading to treatment discontinuation of at least one Food and Drug Administration (FDA)-approved line of therapy (except somatostatin analogs); prior lines of therapy must include one of the following: everolimus, sunitinib, or lutetium Lu 177 dotatate in patients with pancreatic NET; everolimus in patients with lung NET; everolimus or lutetium Lu 177 dotatate in patients with gastrointestinal NET
- Prior treatment (except somatostatin analogs) with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, and/or radiation must be completed at least 28 days prior to registration
- Prior treatment with somatostatin analogs is allowed, and continuation of treatment with somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- Prior systemic treatment with radionuclide therapy must be completed at least 6 weeks prior to registration
- Prior treatment with hepatic artery embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies is allowed if measurable disease remains outside of the treated area or if there is documented disease progression in a treated site; prior liver-directed or other ablative treatment must be completed at least 28 days prior to registration
- Prior treatment with cabozantinib is not allowed
- Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade 1 or less
- Patients must have completed any major surgery at least 12 weeks prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior to registration; complete wound healing from major surgery must have occurred at least 28 days prior to registration, and complete wound healing from minor surgery must have occurred at least 10 days prior to registration
-
Patient History
- No class III or IV congestive heart failure (CHF) within 6 months of registration
- No clinically significant cardiac arrhythmia within 6 months of registration
- No unstable angina or myocardial infarction (MI) within 6 months of registration
- No thromboembolic events within 6 months of registration (including [incl.] stroke, transient ischemic attack [TIA], deep vein thrombosis [DVT], & pulmonary embolism [PE])
- No known history of congenital long QT syndrome
- No uncontrolled hypertension within 14 days of registration (defined as systolic blood pressure [SBP] >= 150 mmHg and/or diastolic blood pressure [DBP] >= 90 mmHg despite optimal medical management)
- No clinically significant GI bleeding within 6 months of registration
- No clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within 6 months of registration including, but not limited to: active peptic ulcer, known endoluminal metastatic lesion(s) with history of bleeding, inflammatory bowel disease, or other gastrointestinal conditions with increased risk of perforation
- No GI perforation within 6 months of registration
- No known tumor with invasion into the GI tract from the outside causing increased risk of perforation or bleeding within 28 days of registration
- No radiologic or clinical evidence of pancreatitis
- No known cavitary lung lesions
- No known endobronchial lesions involving the main or lobar bronchi and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage; (CT with contrast is recommended to evaluate such lesions)
- No hemoptysis greater than 1/2 teaspoon (2.5 mL) or any other signs of pulmonary hemorrhage within the 3 months prior to registration
- No known tumor invading or encasing any major blood vessels
- No history of non-healing wounds or ulcers within 28 days of registration
- No history of fracture within 28 days of registration
- No brain metastases or cranial epidural disease unless adequately treated, stable, and off steroid support for at least 4 weeks prior to registration
- No known medical condition causing an inability to swallow oral formulations of agents
- No history of allergic reaction attributed to compounds of similar chemical or biological composition to cabozantinib/placebo
- No "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ; patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years
-
Concomitant Medications
- Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study
- Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months
- Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =< 81 mg/day is allowed; anticoagulation with therapeutic doses of low molecular weight heparin (LMWH) is allowed in patients who are on a stable dose of LMWH for at least 6 weeks prior to registration; treatment with warfarin is not allowed; anticoagulation in patients with brain metastases is not permitted
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study
-
Not pregnant and not nursing
- Women of childbearing potential must have a negative pregnancy test done =< 14 days prior to registration
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months)
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULN
-
Total bilirubin =< 1.5 x ULN
- Except in the case of Gilbert disease, in which case total bilirubin must be =< 3 x ULN
-
Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45 mL/min
-
Albumin >= 2.8 g/dL
-
Potassium within normal limits (WNL)
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal thyroid stimulating hormone (TSH), if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Phosphorus WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Calcium WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Magnesium WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
-
Urine protein to creatinine (UPC) ratio =< 1
-
QT interval corrected for heart rate using Fridericia's formula (QTcF) =< 500 msec
-
TSH WNL
- Supplementation is acceptable to achieve a value WNL; in patients with low albumin levels, a corrected calcium value WNL is acceptable; in patients with abnormal TSH, if free T4 is normal and patient is clinically euthyroid, patient is eligible
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm I (cabozantinib S-malate)
Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. |
Ancillary studies
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Given PO
Andre navn:
Undergo blood and urine sample collection
Andre navn:
Undergo x-ray
Andre navn:
|
|
Placebo komparator: Arm II (placebo)
Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression. |
Ancillary studies
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Given PO Undergo blood and urine sample collection
Andre navn:
Undergo x-ray
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: 36 months
|
Will be assessed per Response Evaluation Criteria in Solid Tumors 1.1 determined by retrospective independent central review. Will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The stratification factors will be used for the analysis. The hazard ratio (HR) for PFS will be estimated using a stratified Cox proportional hazards model, and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median PFS for each treatment arm. |
36 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: 60 months
|
The analyses for OS will follow intent-to-treat (ITT) principle and will be conducted separately within each cohort (pancreatic neuroendocrine tumor [NET] and carcinoid tumor). The distribution of OS will be estimated using the method of Kaplan-Meier. The median OS, along with the 95% CI, will be estimated by the two treatment groups. Overall survival will be compared between treatment arms using the stratified log-rank test at a one-sided cumulative 2.5% level of significance. The stratified Cox regression will be used to estimate the HR of OS, along with the 95% CI. A hierarchical approach will be used to control for family-wise type-I error rate, therefore OS will be formally statistically tested only if the primary efficacy endpoint, PFS, is statistically significantly different between the two treatment groups. |
60 months
|
|
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: 60 months
|
For CTCAE data, the frequency tables will be reviewed to determine the patterns. The overall adverse event rates will be compared between treatment groups using Chi-square test (or Fisher's exact test if the data in contingency table is sparse). PRO-CTCAE data will, at minimum, be analyzed similarly to CTCAE data. The initial analysis of each PRO-CTCAE item will use all available scores in an analysis which mirrors the approach used for the CTCAE data. Supplemental analysis will use model-based multiple imputation incorporating baseline patient characteristics and physician-rated performance status. CTCAE data may be incorporated as auxiliary data into multiple imputation models for AEs which are captured by both PRO-CTCAE and CTCAE. Results from supplemental analysis will be descriptively compared to the results of the initial analysis to assess the robustness of results to missing data. Additional analyses of PRO-CTCAE data beyond those specified above may be undertaken. |
60 months
|
|
Radiographic Response Rate
Tidsramme: 36 months
|
Will be defined as the proportion of patients in each arm whose best response is either complete response (CR) or partial response (PR). Radiographic response rate for both cohorts: the analyses for confirmed radiographic response rate will follow the ITT principle and will be conducted separately within each cohort (pancreatic NET and carcinoid tumor). The proportion of patients with either confirmed CR or confirmed PR as their best response will be estimated using point estimates and 95% confidence intervals. Radiographic response rate will be compared between treatment arms using the 2-sample z-test to compare sample proportion at a one-sided 2.5% level of significance. |
36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Jennifer A Chan, Alliance for Clinical Trials in Oncology
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.
- Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13;392(7):653-665. doi: 10.1056/NEJMoa2403991. Epub 2024 Sep 16.
- Strosberg JR, Zemla T, Geyer S, Pulsipher S, Ou FS, Behr S, Raj N, Vijayvergia N, Dasari A, O'Reilly EM, Meyerhardt JA, Wolin EM, Halfdanarson TR, Chan JA. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocr Relat Cancer. 2026 Jan 24;33(1):e250415. doi: 10.1530/ERC-25-0415. Print 2026 Jan 1.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer, kjertel og epitel
- Adenom
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Neoplasmer i bukspyttkjertelen
- Nevroendokrine svulster
- Adenom, øycelle
- Ikke fungerende pankreas endokrin tumor
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Fysiske fenomener
- Utstyr og forsyninger
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Elektromagnetiske fenomener
- Magnetiske fenomener
- Elektromagnetisk stråling
- Stråling
- Stråling, ioniserende
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Røntgenbilder
- Cabozantinib
- Fantomer, avbildning
Andre studie-ID-numre
Andre studie-ID-numre
- NCI-2017-02297
- U10CA180821 (U.S. NIH-stipend/kontrakt)
- NCI-2017-02297 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- A021602 (Annen identifikator: CTEP)
- A021602 (Annen identifikator: Alliance for Clinical Trials in Oncology)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .